And one of the other areas I wanted to ask you is the supply chains for our medicines. It seems that a lot of the medicines now have APIs from China, the starting materials from China and India and there's a certain vulnerability there. And I know that China is also focusing a lot on their biomedical research and they're enhancing their capabilities. What can we do to stem this tide? (04:37–04:51)
CLAIM
Asserts that many medicines have active pharmaceutical ingredients sourced from China and India, creating vulnerabilities.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
